ReviewInfection2026
Ebola virus disease in the modern era: pathogenesis, therapeutic advances, vaccine strategies, and global health preparedness.
Review in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ebola virus disease (EVD) remains one of the most severe and complex viral hemorrhagic fevers confronting global public health systems. Since its first recognized emergence in 1976, recurrent outbreaks caused primarily by Zaire ebolavirus have demonstrated the extraordinary epidemic potential of filoviruses, particularly in regions with fragile healthcare infrastructure. The unprecedented West African epidemic of 2013-2016 fundamentally altered scientific understanding of Ebola virus transmission, pathogenesis, clinical progression, and outbreak management. Subsequent outbreaks in the Democratic Republic of Congo and Uganda have further emphasized the persistent risk posed by Ebola virus disease despite advances in diagnostics, therapeutics, and vaccination strategies. Ebola virus infection is characterized by extensive immune dysregulation, aberrant inflammatory responses, endothelial dysfunction, coagulopathy, and progressive multiorgan injury. Recent studies have significantly expanded understanding of viral persistence, post-Ebola syndrome, host immune responses, and mechanisms of viral immune evasion. Parallel developments in molecular diagnostics, genomic surveillance, monoclonal antibody therapy, and recombinant vaccine platforms have substantially improved survival outcomes and epidemic control measures. Although India has not experienced endemic Ebola outbreaks, globalization and increasing international mobility have heightened the possibility of imported infections, necessitating robust preparedness frameworks. Following the West African epidemic, India strengthened airport surveillance, laboratory biosafety capacity, integrated disease surveillance systems, and emergency outbreak-response protocols. However, substantial challenges remain regarding rapid diagnostics, healthcare infrastructure, biosafety training, and public awareness. This review critically examines current advances in Ebola virus epidemiology, molecular biology, pathogenesis, clinical manifestations, diagnostics, therapeutics, vaccine development, and public health preparedness, with particular emphasis on implications for India and future global health security.
Indexed as
Identifiers
42579070What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.